Post by Waters Corporation

Today, we announce the launch of the BioResolve™ Peptide and GTxResolve™ Lipid Phenyl-Hexyl+ and C18+ Columns, a first-of-its-kind reversed-phase column platform designed to tackle a persistent biopharmaceutical challenge: reliably separating structurally and chemically similar impurities in GLP-1 peptides, insulin, and lipid nanoparticles (LNPs) to support the development of safe, effective drug products. “We have made simultaneous advances in both chemistry and particle physics to deliver the first columns Waters has introduced to market specifically QC  batch-tested for GLP‑1 analysis and lipid nanoparticles, solving a longstanding customer pain point,” said Erin Chambers, Vice President &  General Manager, Consumables & Lab Automation, Waters Analytical Sciences, Waters Corporation. “BioResolve Peptide and GTxResolve Lipid Columns are designed to resolve chemically similar GLP‑1 impurities and LNP components faster when speed matters, and with extraordinary resolution when certainty is required. The result is simpler method development, regulatory‑ready data, and faster, highly reproducible methods, ultimately helping to reduce cost burdens on important new therapeutics.” Visit the newsroom to learn more: https://bit.ly/3Qq88gw